Furthermore, the P53 promoter assay results suggest that one of the most significant non-catalytic regulatory functions of FBP1 is to stimulate the expression of the tumor-suppressor P53 gene, whose downregulation or mutation characterizes a distinct feature of AML [31,32]. Here, FBP1 is linked to acute myeloid leukemia.